D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. - Wikidata - awgldk - TriplyDB

D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures.

D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures.

http://www.wikidata.org/entity/Q53989493

about

Polarized axonal surface expression of neuronal KCNQ channels is mediated by multiple signals in the KCNQ2 and KCNQ3 C-terminal domains Discovery, Synthesis, and Structure–Activity Relationship of a Series of N -Aryl-bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener Neural KCNQ (Kv7) channels Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells Diverse mechanisms of antiepileptic drugs in the development pipeline Molecular targets for antiepileptic drug development Retigabine: has the orphan found a home?Preclinical antiepileptic actions of selective serotonin reuptake inhibitors--implications for clinical trial design New and emerging treatments for epilepsy: review of clinical studies of lacosamide, eslicarbazepine acetate, ezogabine, rufinamide, perampanel, and electrical stimulation therapy Homeostasis or channelopathy? Acquired cell type-specific ion channel changes in temporal lobe epilepsy and their antiepileptic potential Preclinical research in Rett syndrome: setting the foundation for translational success.Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers.Is there a role for potassium channel openers in neuronal ion channel disorders?Activation of voltage-gated KCNQ/Kv7 channels by anticonvulsant retigabine attenuates mechanical allodynia of inflammatory temporomandibular joint in rats.New anti-epileptic drugs.Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data.Voltage-gated potassium channels at the crossroads of neuronal function, ischemic tolerance, and neurodegeneration.The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy.Vasorelaxant effects of novel Kv 7.4 channel enhancers ML213 and NS15370 Potassium channels: how genetic studies of epileptic syndromes open paths to new therapeutic targets and drugs.Emerging drugs for epilepsy.Novel anticonvulsant medications in development.Ezogabine: a new angle on potassium gates.Oxidative modification of M-type K(+) channels as a mechanism of cytoprotective neuronal silencing.Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures The therapeutic potential of neuronal KCNQ channel modulators.Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine.Clinical utility of adjunctive retigabine in partial onset seizures in adults.Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis.The Effects of the KCNQ Openers Retigabine and Flupirtine on Myotonia in Mammalian Skeletal Muscle Induced by a Chloride Channel Blocker.Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy.Combinatorial augmentation of voltage-gated KCNQ potassium channels by chemical openers.Novel anticonvulsant drugs targeting voltage-dependent ion channels.One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders.The new KCNQ2 activator 4-Chlor-N-(6-chlor-pyridin-3-yl)-benzamid displays anticonvulsant potential.Retigabine.Antiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study.Inside job: ligand-receptor pharmacology beneath the plasma membrane.Enhancement of inhibitory neurotransmission and inhibition of excitatory mechanisms underlie the anticonvulsant effects of Mallotus oppositifolius.Rapid loss of efficacy to the antiseizure drugs lamotrigine and carbamazepine: a novel experimental model of pharmacoresistant epilepsy

P2860

Q24545908-5FEC6234-BC28-4424-AE6D-E19884B8139E Q24634116-8F7F469C-CB71-4816-A807-BEBF66316898 Q24644947-61E4B05E-5675-42B6-B80A-BF6280627A28 Q24674102-DD3649C1-3123-4921-892E-BEAB5BB3EADD Q24675330-8C305420-8C07-4FE1-8DA8-D834EC9A3E0A Q24683346-8C8AC09E-088F-4236-A14E-1DC9E33A63C7 Q24685444-5855FB7F-B24F-4900-B215-4AAAEF028584 Q26850811-661549C3-08FA-4636-9796-27A79D63F23B Q27007942-C35B904B-15FC-411C-BFFA-B0CEE6231CED Q28080655-872F5257-6808-4D44-B37B-8CFA3E46B686 Q30527828-0E3AEDCB-E327-4C7F-BBC2-05370DD86CB6 Q33845614-D9A5E9DA-4FBF-44E6-986E-06230E181AC9 Q34075106-DD3CB505-FF72-4134-BCF4-668DDF2F4AC3 Q34114419-E29CDBD0-D728-4FFA-AD99-AB0F64040BF2 Q34119473-C22E3EC5-0C48-4993-95D2-6B7A0DA0B008 Q34333196-9A5E152F-A11A-4097-A727-88589CA2E720 Q34390785-BABA8E74-C7EE-4FD2-96CC-CDD48E5D82F1 Q34393213-A982289A-D2B4-485D-87BD-F23FEEFAC42E Q34402797-5B91D7E3-A494-4E3C-BD24-E633CE2A0693 Q34558128-ECA37154-652C-4239-BD0C-EA1CAA1FBC18 Q34688725-5075AA40-462C-4FE5-A1BE-ED0A9554B9AD Q34974862-9B678C3A-BFB1-478D-A4BA-DC19F832FDE2 Q35052160-A9C1B209-1A5C-4938-8F42-47CD7E26B43A Q35102221-6223FCCB-9793-4306-8DEE-BAB0C902CCD0 Q35117817-087DBD8A-6F64-4ECD-8E34-2086209740CA Q35593939-29773CA6-54AE-4B07-9849-32BC3C476E57 Q35683922-539F834F-BAF8-4086-83D2-880381304714 Q35717049-308B6CA4-2112-46B0-93C7-8EE2107BECDE Q35761335-B22115D3-C1BE-4135-9C46-EE7049B7A927 Q35872543-50E8D184-9A29-4D1C-9DDF-B42F65E5F5CF Q36144410-FA21A981-CD07-46DE-9C4F-3607E82FD8B5 Q36498532-CEBAF9A0-BA72-4B7D-AD37-6D053F011C21 Q36600282-5208A27F-95B1-4659-B25A-091FAB82D00A Q36603168-6C30211A-E24F-4B33-B64A-8B8A92D53C37 Q36675813-63BC4199-0703-4139-B33C-3F8F7FAF142A Q36697501-864D2589-5E03-4A65-AAE1-926213A0A08A Q36958975-79615128-7E8C-4F9E-8D95-DE57B4A52E49 Q36989788-DED01FDC-FB63-41D5-96F7-16236AD8421F Q37058186-97E990BF-68F6-49F3-944D-46773F91D7D5 Q37074600-0A76A095-280B-4D7D-BF4D-D93F1160593D

P2860

D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures.

http://www.wikidata.org/entity/Q53989493

description

1996 nî lūn-bûn

@nan

1996年の論文

@ja

1996年学术文章

@wuu

1996年学术文章

@zh-cn

1996年学术文章

@zh-hans

1996年学术文章

@zh-my

1996年学术文章

@zh-sg

1996年學術文章

@yue

1996年學術文章

@zh

1996年學術文章

@zh-hant

name

D-23129: a new anticonvulsant ...... models of epileptic seizures.

@en

D-23129: a new anticonvulsant ...... models of epileptic seizures.

@nl

type

label

D-23129: a new anticonvulsant ...... models of epileptic seizures.

@en

D-23129: a new anticonvulsant ...... models of epileptic seizures.

@nl

prefLabel

D-23129: a new anticonvulsant ...... models of epileptic seizures.

@en

D-23129: a new anticonvulsant ...... models of epileptic seizures.

@nl

P1433

Q53989493-1DBF55DE-AAF3-4CAF-82B8-CDC2330566AB

P1476

Q53989493-B1B63006-9E63-4487-BDC5-F578AB25316C

P2093

Q53989493-1AF92658-E137-4C32-95C5-B4A87C1E095D

Q53989493-2E3FAD10-A4F7-4F20-84F3-7586ED8E5C08

Q53989493-319D4C0D-210B-4B76-8BC4-74EA36247402

Q53989493-49899841-29D0-4B85-AB07-BDF3448C64FD

Q53989493-4E381BEE-6406-40A6-A684-27C280A55945

Q53989493-57A1177F-FEF5-45F4-B5CE-3175488776CF

Q53989493-807BBB78-AC95-4C99-B82B-DDAE4B7F79C6

Q53989493-BB7DBB2E-AD78-45EB-A887-2455C7B6DF74

Q53989493-D76DD67C-1D69-4C14-AB17-0EF55BEAD5DE

Q53989493-D77A3A69-672F-45B0-BB39-F891F43E5543

P304

Q53989493-632B67E6-E5C7-43DE-8076-9B6D402DC032

P31

Q53989493-32B53594-9C2B-4C20-8A19-9BB420C7ADB0

P356

Q53989493-30992B09-3A60-41D1-BC10-0BBE7FB1C5EA

P433

Q53989493-456D1725-5F41-4893-8EFB-AE6FCF6357B0

P478

Q53989493-9CD4B576-B915-4E85-9EBD-5D0C3801BB3C

P577

Q53989493-01AE60B3-4E59-41A8-B420-14F0D3AEE6C0

P698

Q53989493-F4C0C32A-6DB7-4A48-AF25-C7DD8DE7225C

P356

0920-1211(95)00101-8

P1433

Epilepsy Research

P1476

D-23129: a new anticonvulsant ...... models of epileptic seizures.

@en

P2093

A Rostock

http://www.w3.org/2001/XMLSchema#string

B Kutscher

http://www.w3.org/2001/XMLSchema#string

C Rundfeldt

http://www.w3.org/2001/XMLSchema#string

C Tober

http://www.w3.org/2001/XMLSchema#string

D Hönack

http://www.w3.org/2001/XMLSchema#string

E E Polymeropoulos

http://www.w3.org/2001/XMLSchema#string

H H Wolf

http://www.w3.org/2001/XMLSchema#string

H S White

http://www.w3.org/2001/XMLSchema#string

J Engel

http://www.w3.org/2001/XMLSchema#string

R Bartsch

http://www.w3.org/2001/XMLSchema#string

P304

211-223

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/0920-1211(95)00101-8

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

1996-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8739124

http://www.w3.org/2001/XMLSchema#string